Body Composition and Inflammation as Emerging Sex-Specific Prognostic Factors in Patients with Advanced Cutaneous Melanoma Undergoing Immune Checkpoint-Inhibition Therapy: A Prospective Pilot Study
Oncology Research and Treatment · 13.06.2025 · 48 (11) · 729-739
DOI: 10.1159/000546797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, online erschienen am 13.06.2025. Verfasst von Jana Knuever und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Duesseldorf, University Hospital Cologne, Univ…. Hauptthemen laut MEDLINE: Melanoma, Body Composition, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Introduction
The distribution of muscle and adipose tissues masses physiologically follow sex-specific patterns. On the other hand, the clinical and biological consequences of pathologic body composition, i.e., sarcopenia or obesity, also depend on tissue distribution patterns. Although obesity-associated inflammation has been correlated with survival benefits of cancer patients undergoing immune checkpoint inhibition (ICI) therapy, detailed and sex-specific body composition analyses are widely missing. Here, we prospectively analyzed body composition and serum parameters of inflammation and protein metabolism in patients with advanced melanoma before and 3 months after initiation of ICI therapy.
Methods
Between 2016 and 2018, consecutive patients with advanced cutaneous melanoma were recruited into the study at our cancer center (Skin Cancer Center, CIO, University Hospital Cologne, Germany). Blood samples and body composition based on bioelectrical impedance analysis (BIA) were assessed before ICI therapy initiation (T1) and after 3 months (T2). Correlation of blood parameters with body composition as well as progression-free (PFS) and overall survival (OS) was analyzed in sex-specific subgroups.
Results
From a total of 54 patients, 25 were women and 29 were men. In women, a high muscle mass at T1 was the strongest marker for longer PFS (HR 0.84; 95% CI: 0.74–0.98; p = 0.024), while in men (n = 29), high phase angle values at T1 correlated with significantly longer PFS (HR 0.48; 95% CI: 0.26–0.90; p = 0.023). Regarding OS, muscle mass status at T1 remained the strongest predictor for longer survival in women (HR 0.85; 95% CI: 0.72–0.99; p = 0.033), while in men, increased leukocyte blood counts at T1 were associated with the poorest OS (HR 1.36; 95% CI: 1.14–1.62; p = 0.001). Inflammation and the immuno-nutritional score mGPS correlated with body composition parameters in a sex-specific manner. However, we did not observe an impact of dynamic changes between T1 and T2 in all analyzed parameters.
Conclusion
Our data suggest that BIA-derived markers are associated with the prognosis of melanoma patients undergoing ICI therapy in a sex-specific manner. Selected body composition parameters correlate differently with blood markers of inflammation and protein metabolism in men and women. If validated in larger trials, these assessments might improve individualized supportive care and clinical risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany, jana.naetlitz@ukbonn.de.
- Centre for Skin Diseases, Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany, jana.naetlitz@ukbonn.de.
- Department of Dermatology and Allergology, Technical University of Munich, Munich, Germany.
- Department of Dermatology and Venerology, Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of Dermatology, Venereology and Allergology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
- Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital, Munich, Germany.
Zitieren
APA
Knuever, J., Persa, O. D., Gerecht, L., Schlaak, M., & Theurich, S. (2025). Body Composition and Inflammation as Emerging Sex-Specific Prognostic Factors in Patients with Advanced Cutaneous Melanoma Undergoing Immune Checkpoint-Inhibition Therapy: A Prospective Pilot Study. Oncology Research and Treatment, 48(11), 729-739. https://doi.org/10.1159/000546797
Vancouver
Knuever J, Persa OD, Gerecht L, Schlaak M, Theurich S. Body Composition and Inflammation as Emerging Sex-Specific Prognostic Factors in Patients with Advanced Cutaneous Melanoma Undergoing Immune Checkpoint-Inhibition Therapy: A Prospective Pilot Study. Oncology Research and Treatment. 2025;48(11):729-739. doi:10.1159/000546797
BibTeX
@article{Knuever2025,
author = {Knuever, Jana and Persa, Oana-Diana and Gerecht, Lukas and Schlaak, Max and Theurich, Sebastian},
title = {Body Composition and Inflammation as Emerging Sex-Specific Prognostic Factors in Patients with Advanced Cutaneous Melanoma Undergoing Immune Checkpoint-Inhibition Therapy: A Prospective Pilot Study},
journal = {Oncology Research and Treatment},
year = {2025},
volume = {48},
number = {11},
pages = {729--739},
doi = {10.1159/000546797}
}
EUVIMED